According to the biological function of diverse forms of EGFR in NSCLC, EGFR-targeted therapy is divided into two parts: “EGFR mutant targeted therapy” and “wt EGFR targeted therapy.” Among NSCLC patients, ~10%–30% have lung cancers with EGFR mutations (118). Here, EGFR is linked to lung carcinoma.